Small molecule

Articles

• sunitinib
  2 June 2009

  Definition: Sunitinib (marketed as Sutent, and previously known as SU11248) is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTKs) inhibitor (multiRTKs inhibitors).
  Sunitinib was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26, 2006.
  The concept was of a ATP analogue that would compete with ATP for binding to the catalytic site of receptor tyrosine kinases. This concept led (...)

• dasatinib
  2 September 2008

  WP
  Definition: Dasatinib is a dual inhibitor of the src and abl tyrosine kinases. It was approved by the Federal Drug Administration for the treatment of imatinib mesylate-resistant chronic myeloid leukemia.
  Dasatinib inhibits juxtamembrane domain mutant KIT-D816V autophosphorylation and KIT-dependent activation of down stream signaling important for cell growth and survival of neoplastic cells.
  Additionally, dasatinib induces apoptosis in mast cell and leukemia cell lines expressing (...)

• crizotinib
  10 June 2010

  Pfizer drug crizotinibPF-02341066 or 1066, PF-02341066, Xalkori Wikipedia
  Molecular target: ALK
  Definition: Crizotinib is an ALK inhibitor , ROS1 inhibitor and MET inhibitor .
  Crizotinib is undergoing clinical trials testing its safety and efficacy in anaplastic large cell lymphoma, neuroblastoma, advanced non-small cell lung carcinoma (NSCLC ).
  Crizotinib is an oral ALK (anaplastic lymphoma kinase) inhibitor under study in patients with advanced NSCLC carrying the echinoderm (...)